Á lódáil...
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
BACKGROUND: Activation of the vascular endothelial growth factor receptor (VEGFR) and the oncogenic Src pathway has been implicated in the development of castration-resistant prostate cancer (CRPC) in preclinical models. Cediranib and dasatinib are multi-kinase inhibitors targeting VEGFR and Src res...
Na minha lista:
Foilsithe in: | Invest New Drugs |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
2014
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4281773/ https://ncbi.nlm.nih.gov/pubmed/24788563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0106-5 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|